CN Stock MarketDetailed Quotes

301211 Hubei Biocause Heilen Pharmaceutical

Watchlist
  • 19.92
  • -1.07-5.10%
Post Market Nov 18 15:00 CST
5.74BMarket Cap53.98P/E (TTM)

Hubei Biocause Heilen Pharmaceutical Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(Q9)Sep 30, 2024
(Q6)Jun 30, 2024
(Q3)Mar 31, 2024
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
Total operating revenue
-38.43%333.99M
-40.39%241.87M
-28.57%138.06M
28.76%663.03M
56.93%542.45M
68.80%405.76M
50.72%193.29M
-4.76%514.91M
-17.37%345.66M
-13.17%240.38M
Operating revenue
-38.43%333.99M
-40.39%241.87M
-28.57%138.06M
28.76%663.03M
56.93%542.45M
68.80%405.76M
50.72%193.29M
-4.76%514.91M
-17.37%345.66M
-13.17%240.38M
Other operating revenue
----
56.98%3.43M
----
256.20%11.61M
----
177.02%2.19M
----
273.24%3.26M
----
78.67%789.39K
Total operating cost
-29.52%263.84M
-39.85%164.43M
-34.36%94.97M
24.31%467.72M
42.95%374.33M
51.13%273.39M
45.38%144.69M
-10.97%376.27M
-17.28%261.86M
-13.06%180.9M
Operating cost
-27.50%233.02M
-37.05%154.79M
-34.58%85.71M
8.32%396.67M
31.90%321.42M
43.70%245.87M
45.44%131.01M
2.55%366.22M
-8.86%243.68M
-1.73%171.1M
Operating tax surcharges
-35.90%2.86M
-29.28%2.2M
-68.57%575.61K
49.40%5.92M
95.91%4.47M
82.02%3.12M
348.40%1.83M
-32.81%3.96M
-10.79%2.28M
12.05%1.71M
Operating expense
-5.17%16.57M
-22.22%10.4M
-10.68%5.88M
61.58%24.08M
26.70%17.47M
44.87%13.37M
2.43%6.58M
24.50%14.91M
64.08%13.79M
68.73%9.23M
Administration expense
-17.30%29.23M
1.11%19.23M
-1.57%9.6M
6.35%38.89M
-5.53%35.34M
-16.99%19.02M
-16.91%9.76M
31.66%36.56M
52.66%37.41M
31.73%22.91M
Financial expense
-12.23%-44.11M
-47.06%-41.49M
-52.82%-17.74M
22.40%-50.62M
22.03%-39.3M
16.17%-28.21M
15.59%-11.61M
-4,199.45%-65.23M
-3,900.52%-50.4M
-2,046.11%-33.65M
-Interest expense (Financial expense)
-10.12%183.05K
-6.24%125.05K
6.01%63.25K
-10.74%307.43K
--203.66K
--133.38K
--59.67K
--344.41K
----
----
-Interest Income (Financial expense)
-19.30%-43.3M
-60.99%-39.58M
-39.13%-17.11M
21.60%-47.84M
21.14%-36.29M
19.99%-24.58M
15.27%-12.3M
-2,445.56%-61.02M
-38,070.13%-46.02M
-29,782.57%-30.72M
Research and development
-24.80%26.27M
-4.55%19.3M
53.73%10.94M
165.94%52.77M
131.24%34.93M
110.62%20.21M
53.89%7.12M
8.55%19.84M
21.91%15.11M
22.16%9.6M
Credit Impairment Loss
-1,929.16%-666.97K
18.64%-614.54K
-177.21%-326.5K
-65.28%596.61K
-101.87%-32.87K
-157.73%-755.38K
-56.82%422.85K
268.49%1.72M
300.05%1.76M
362.69%1.31M
Asset Impairment Loss
----
----
----
----
---1.53M
---1.53M
---1.53M
----
----
----
Other net revenue
319.93%12.81M
159.87%3.7M
359.12%1.26M
-0.51%10.03M
-68.91%3.05M
-76.03%1.42M
-109.45%-484.46K
-52.66%10.08M
-22.22%9.81M
-21.59%5.93M
Fair value change income
--10.08M
--2.65M
--947.92K
--4.02M
----
----
----
----
----
----
Invest income
--1.18M
--975.1K
--34.44K
----
----
----
----
----
----
----
Asset deal income
----
----
----
327.18%177.18K
-106.93%-2.88K
-151.84%-2.88K
----
156.60%41.48K
162.35%41.48K
107.57%5.55K
Other revenue
-51.98%2.22M
-81.53%684.82K
-3.33%599.48K
-37.08%5.24M
-42.42%4.61M
-19.73%3.71M
-85.05%620.11K
-28.78%8.32M
26.26%8.01M
50.75%4.62M
Operating profit
-51.53%82.96M
-39.36%81.13M
-7.84%44.34M
38.06%205.33M
82.86%171.17M
104.54%133.79M
42.15%48.11M
6.78%148.73M
-18.18%93.61M
-14.28%65.41M
Add:Non operating Income
-55.40%84.43K
145.98%84.43K
790.36%52.08K
--299.28K
197.10%189.3K
-32.46%34.32K
--5.85K
----
3,414.89%63.72K
2,703.29%50.82K
Less:Non operating expense
-19.08%461.9K
83.21%329.03K
-61.43%69.25K
119.49%2.82M
434.93%570.82K
71.69%179.59K
74.51%179.57K
802.76%1.28M
-28.01%106.71K
4,321.53%104.6K
Total profit
-51.65%82.58M
-39.48%80.89M
-7.54%44.32M
37.56%202.82M
82.53%170.79M
104.49%133.65M
42.07%47.94M
5.93%147.44M
-18.11%93.56M
-14.35%65.36M
Less:Income tax cost
-69.86%7.92M
-39.88%12.39M
-13.39%6.94M
23.33%26.7M
75.00%26.27M
88.07%20.61M
38.72%8.02M
23.46%21.65M
0.74%15.01M
31.88%10.96M
Net profit
-48.34%74.66M
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
Net profit from continuing operation
-48.34%74.66M
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
Net profit of parent company owners
-48.34%74.66M
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
Earning per share
Basic earning per share
-48.00%0.26
-38.46%0.24
-7.14%0.13
38.64%0.61
85.19%0.5
105.26%0.39
16.67%0.14
-35.29%0.44
-50.91%0.27
-50.00%0.19
Diluted earning per share
-48.00%0.26
-38.46%0.24
-7.14%0.13
38.64%0.61
85.19%0.5
105.26%0.39
16.67%0.14
-35.29%0.44
-50.91%0.27
-50.00%0.19
Other composite income
Total composite income
-48.34%74.66M
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
Total composite income of parent company owners
-48.34%74.66M
-39.40%68.5M
-6.37%37.38M
40.00%176.12M
83.98%144.51M
107.80%113.04M
42.76%39.92M
3.41%125.79M
-20.94%78.55M
-20.00%54.4M
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
CAS (2007)
Audit Opinions
--
--
--
Unqualified opinion
--
--
--
Unqualified opinion
--
--
Auditor
--
--
--
Daxin Certified Public Accountants (Special General Partnership)
--
--
--
Daxin Certified Public Accountants (Special General Partnership)
--
--
(Q9)Sep 30, 2024(Q6)Jun 30, 2024(Q3)Mar 31, 2024(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022
Total operating revenue -38.43%333.99M-40.39%241.87M-28.57%138.06M28.76%663.03M56.93%542.45M68.80%405.76M50.72%193.29M-4.76%514.91M-17.37%345.66M-13.17%240.38M
Operating revenue -38.43%333.99M-40.39%241.87M-28.57%138.06M28.76%663.03M56.93%542.45M68.80%405.76M50.72%193.29M-4.76%514.91M-17.37%345.66M-13.17%240.38M
Other operating revenue ----56.98%3.43M----256.20%11.61M----177.02%2.19M----273.24%3.26M----78.67%789.39K
Total operating cost -29.52%263.84M-39.85%164.43M-34.36%94.97M24.31%467.72M42.95%374.33M51.13%273.39M45.38%144.69M-10.97%376.27M-17.28%261.86M-13.06%180.9M
Operating cost -27.50%233.02M-37.05%154.79M-34.58%85.71M8.32%396.67M31.90%321.42M43.70%245.87M45.44%131.01M2.55%366.22M-8.86%243.68M-1.73%171.1M
Operating tax surcharges -35.90%2.86M-29.28%2.2M-68.57%575.61K49.40%5.92M95.91%4.47M82.02%3.12M348.40%1.83M-32.81%3.96M-10.79%2.28M12.05%1.71M
Operating expense -5.17%16.57M-22.22%10.4M-10.68%5.88M61.58%24.08M26.70%17.47M44.87%13.37M2.43%6.58M24.50%14.91M64.08%13.79M68.73%9.23M
Administration expense -17.30%29.23M1.11%19.23M-1.57%9.6M6.35%38.89M-5.53%35.34M-16.99%19.02M-16.91%9.76M31.66%36.56M52.66%37.41M31.73%22.91M
Financial expense -12.23%-44.11M-47.06%-41.49M-52.82%-17.74M22.40%-50.62M22.03%-39.3M16.17%-28.21M15.59%-11.61M-4,199.45%-65.23M-3,900.52%-50.4M-2,046.11%-33.65M
-Interest expense (Financial expense) -10.12%183.05K-6.24%125.05K6.01%63.25K-10.74%307.43K--203.66K--133.38K--59.67K--344.41K--------
-Interest Income (Financial expense) -19.30%-43.3M-60.99%-39.58M-39.13%-17.11M21.60%-47.84M21.14%-36.29M19.99%-24.58M15.27%-12.3M-2,445.56%-61.02M-38,070.13%-46.02M-29,782.57%-30.72M
Research and development -24.80%26.27M-4.55%19.3M53.73%10.94M165.94%52.77M131.24%34.93M110.62%20.21M53.89%7.12M8.55%19.84M21.91%15.11M22.16%9.6M
Credit Impairment Loss -1,929.16%-666.97K18.64%-614.54K-177.21%-326.5K-65.28%596.61K-101.87%-32.87K-157.73%-755.38K-56.82%422.85K268.49%1.72M300.05%1.76M362.69%1.31M
Asset Impairment Loss -------------------1.53M---1.53M---1.53M------------
Other net revenue 319.93%12.81M159.87%3.7M359.12%1.26M-0.51%10.03M-68.91%3.05M-76.03%1.42M-109.45%-484.46K-52.66%10.08M-22.22%9.81M-21.59%5.93M
Fair value change income --10.08M--2.65M--947.92K--4.02M------------------------
Invest income --1.18M--975.1K--34.44K----------------------------
Asset deal income ------------327.18%177.18K-106.93%-2.88K-151.84%-2.88K----156.60%41.48K162.35%41.48K107.57%5.55K
Other revenue -51.98%2.22M-81.53%684.82K-3.33%599.48K-37.08%5.24M-42.42%4.61M-19.73%3.71M-85.05%620.11K-28.78%8.32M26.26%8.01M50.75%4.62M
Operating profit -51.53%82.96M-39.36%81.13M-7.84%44.34M38.06%205.33M82.86%171.17M104.54%133.79M42.15%48.11M6.78%148.73M-18.18%93.61M-14.28%65.41M
Add:Non operating Income -55.40%84.43K145.98%84.43K790.36%52.08K--299.28K197.10%189.3K-32.46%34.32K--5.85K----3,414.89%63.72K2,703.29%50.82K
Less:Non operating expense -19.08%461.9K83.21%329.03K-61.43%69.25K119.49%2.82M434.93%570.82K71.69%179.59K74.51%179.57K802.76%1.28M-28.01%106.71K4,321.53%104.6K
Total profit -51.65%82.58M-39.48%80.89M-7.54%44.32M37.56%202.82M82.53%170.79M104.49%133.65M42.07%47.94M5.93%147.44M-18.11%93.56M-14.35%65.36M
Less:Income tax cost -69.86%7.92M-39.88%12.39M-13.39%6.94M23.33%26.7M75.00%26.27M88.07%20.61M38.72%8.02M23.46%21.65M0.74%15.01M31.88%10.96M
Net profit -48.34%74.66M-39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M
Net profit from continuing operation -48.34%74.66M-39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M
Net profit of parent company owners -48.34%74.66M-39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M
Earning per share
Basic earning per share -48.00%0.26-38.46%0.24-7.14%0.1338.64%0.6185.19%0.5105.26%0.3916.67%0.14-35.29%0.44-50.91%0.27-50.00%0.19
Diluted earning per share -48.00%0.26-38.46%0.24-7.14%0.1338.64%0.6185.19%0.5105.26%0.3916.67%0.14-35.29%0.44-50.91%0.27-50.00%0.19
Other composite income
Total composite income -48.34%74.66M-39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M
Total composite income of parent company owners -48.34%74.66M-39.40%68.5M-6.37%37.38M40.00%176.12M83.98%144.51M107.80%113.04M42.76%39.92M3.41%125.79M-20.94%78.55M-20.00%54.4M
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)CAS (2007)
Audit Opinions ------Unqualified opinion------Unqualified opinion----
Auditor ------Daxin Certified Public Accountants (Special General Partnership)------Daxin Certified Public Accountants (Special General Partnership)----

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
CN
Overall
Symbol
Latest Price
% Chg

No Data